Samah Algharib | Immunotherapy | Innovative Research Award

Innovative Research Award

Samah Algharib — Mississippi State University, United States

Samah Algharib
Affiliation Mississippi State University
Country United States
Scopus ID 57211476541
Documents 42
Citations 1,190
h-index 17
Subject Area Immunotherapy
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3336-2855

Samah Algharib is affiliated with Mississippi State University and works within the broad research area of immunotherapy. The documented research record includes studies addressing antibacterial treatment strategies and veterinary infectious disease, including responsive nanogels, controlled-release hydrogels, and diagnostic perspectives related to bovine mastitis. [1] [2] [3]

Abstract

Samah Algharib, affiliated with Mississippi State University, is associated with research spanning immunotherapy, antibacterial treatment strategies, drug delivery, and veterinary infectious disease. The documented publication record includes investigations of pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, slow-release florfenicol hydrogels for intestinal bacterial infections, and contemporary approaches to bovine mastitis diagnosis. These studies collectively address therapeutic delivery, antimicrobial effectiveness, controlled release, and disease identification. The supplied research profile records 42 documents, 1,190 citations, and an h-index of 17, providing bibliometric context for the recognition of research activity in pharmaceutical and biomedical applications. [1] [2] [3]

Keywords

Immunotherapy; antibacterial therapy; florfenicol; nanogels; hydrogels; controlled drug release; Staphylococcus aureus; bovine mastitis; veterinary medicine; pharmaceutical research.

Introduction

Research associated with Samah Algharib addresses biomedical and pharmaceutical questions involving antimicrobial treatment and disease management. Published work examines responsive florfenicol nanogels and hydrogels designed to improve therapeutic delivery, while related veterinary research considers contemporary diagnostic approaches for bovine mastitis. These topics connect pharmaceutical formulation with infectious-disease applications. [1] [2] [3]

Research Profile

The supplied profile identifies immunotherapy as the principal subject area, alongside research themes involving antimicrobial agents, drug-delivery systems, bacterial infections, and veterinary health. The publications demonstrate attention to formulation characteristics, release behavior, antibacterial activity, and diagnostic considerations, providing a multidisciplinary context for pharmaceutical and biomedical investigation. [1] [2] [3]

Research Contributions

The documented studies contribute to research on responsive and controlled antimicrobial delivery. One study investigates pH- and gelatinase-responsive florfenicol nanogels against Staphylococcus aureus, while another examines slow-release florfenicol hydrogels for intestinal bacterial infections. Related work reviews concepts and advances in bovine mastitis diagnosis, connecting treatment research with disease detection. [1] [2] [3]

Publications

The supplied publication set includes research on enhanced antibacterial effects of pH/gelatinase-responsive florfenicol nanogels, manipulated slow release of florfenicol hydrogels, and basic concepts and recent advances in bovine mastitis diagnosis. These publications collectively reflect research interests spanning pharmaceutical formulation, antimicrobial intervention, controlled release, veterinary disease management, and diagnostic science. [1] [2] [3]

Research Impact

The supplied bibliometric profile records 42 documents, 1,190 citations, and an h-index of 17. These indicators provide quantitative context for the reach of the indexed research record, while the cited publications demonstrate applications in antimicrobial treatment, drug delivery, and veterinary diagnostics. Bibliometric measures should be interpreted alongside publication quality and research context. [1] [2] [3]

Award Suitability

For an Innovative Research Award, the documented work provides evidence of research involving responsive nanogels, controlled-release hydrogels, antibacterial treatment, and veterinary diagnostic perspectives. The combination of formulation-oriented pharmaceutical research and infectious-disease applications demonstrates identifiable innovation themes that can be considered alongside the supplied publication record, citation indicators, affiliation, and the specific criteria established by the awarding organization. [1] [2] [3]

Conclusion

Samah Algharib’s documented research profile encompasses immunotherapy-related interests, antimicrobial delivery, florfenicol formulations, bacterial infection treatment, and bovine mastitis diagnostics. The supplied record combines publication activity with reported citation indicators and research addressing practical biomedical and veterinary challenges. These materials provide a structured basis for academic recognition under the stated Innovative Research Award category. [1] [2] [3]

References

  1. Enhanced antibacterial effect of pH/gelatinase-responsive florfenicol nanogels against Staphylococcus aureus. (2025). PubMed.
    https://pubmed.ncbi.nlm.nih.gov/40292404/
  2. Manipulated slow release of florfenicol hydrogels for effective treatment of anti-intestinal bacterial infections. (n.d.). International Journal of Nanomedicine, Dove Medical Press.
    https://www.dovepress.com/manipulated-slow-release-of-florfenicol-hydrogels-for-effective-treatm-peer-reviewed-fulltext-article-IJN
  3. Basic concepts, recent advances, and future perspectives in the diagnosis of bovine mastitis. (2023). Journal of Veterinary Science. https://doi.org/10.4142/jvs.23147
    https://vetsci.org/DOIx.php?id=10.4142/jvs.23147

Rulla Tamimi | Immunotherapy | Best Researcher Award

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation

Prof. Peng SHI|Immunotherapy|Best Researcher Award

Prof. Peng SHI-Immunotherapy-Best Researcher Award

Prof. Peng SHI atCity University of Hong ,Hong Kong

Author Profile

Orcid

Early Academic Pursuits 🎓

Peng Shi’s academic journey began with a solid foundation in electrical engineering, earning a Bachelor of Engineering degree from Wuhan University, China, in 2002. His keen interest in blending engineering with biological systems led him to pursue advanced studies in biomedical engineering at Columbia University, USA, where he earned both an M.Phil. in 2006 and a Ph.D. in 2009. At Columbia, Dr. Shi honed his expertise in interdisciplinary research, laying the groundwork for his future contributions to translational neuro-engineering and bioelectronics.

Professional Endeavors 👨‍🏫

Dr. Shi’s career reflects a trajectory of academic excellence and innovation. After completing his Ph.D., he served as a Postdoctoral Fellow at the Department of Electrical Engineering, Massachusetts Institute of Technology (MIT), USA (2010–2011), where he worked alongside leading researchers to advance the frontiers of bioelectronics and synthetic biology.

In 2011, Dr. Shi joined the Department of Biomedical Engineering at the City University of Hong Kong as an Assistant Professor. His dedication and groundbreaking work earned him an early promotion to Associate Professor (with tenure) in 2016 and subsequently to Full Professor in 2020. Notably, these advancements highlight his exceptional contributions to his field within a remarkably short timeframe.

Contributions and Research Focus 🔬

Dr. Shi is a pioneer at the intersection of neuroscience and engineering, leveraging cutting-edge methodologies like nano-/micro-fabrication, bioelectronics, synthetic biology, high-resolution microscopy, and artificial intelligence. His research addresses critical challenges in translational neuro-engineering, emphasizing the development of high-throughput technologies and bioelectronic platforms to create innovative therapeutic systems.

His prolific output includes more than 90 publications in prestigious journals such as Nature Reviews Materials, Nature Biomedical Engineering, PNAS, Science Advances, and Advanced Materials. These works underscore his influence in fields spanning materials science, bioengineering, and neurotechnology. Beyond academic publishing, Dr. Shi has filed 18 patents, with several granted in the US and China. Some of these patents have served as the technological foundation for two biotech spin-offs, ANRim Biotechnology Limited and Electro-Ohmics, exemplifying the translational impact of his research.

Accolades and Recognition 🏅

Dr. Shi’s excellence in research and innovation has been recognized with numerous prestigious awards and appointments:

  • 2015: Awarded the 1000 Young Talent Program by the National Natural Science Foundation of China (NSFC), a testament to his exceptional potential in scientific leadership.
  • 2018: Received the Special Recognition for Young Scholars from the World Cultural Council for his contributions to advancing global scientific understanding.
  • 2022: Appointed as Associate Editor of Brain Research (Elsevier), reflecting his influence in shaping the field of neuroscience.
  • 2023: Selected for the Biology and Medicine Panel of the Hong Kong RGC Joint Research Schemes, recognizing his leadership in biomedical research.

Dr. Shi has also delivered over 100 invited talks at global conferences, workshops, and academic institutions, further solidifying his reputation as a thought leader.

Impact and Influence 🌍

Dr. Shi’s innovations have a far-reaching impact, bridging the gap between basic research and clinical applications. His high-throughput bioelectronic platforms are revolutionizing therapeutic strategies, particularly in the realm of neuro-engineering. The biotech companies he co-founded, such as ANRim Biotechnology Limited, have secured significant funding, including RMB15M in angel investments, and are valued at HKD70M, demonstrating his success in translating academic research into viable commercial solutions.

As a grant referee for organizations like the NSFC, European Research Council, and Hong Kong UGC, Dr. Shi contributes to shaping the global research landscape. His expertise is further acknowledged through his role as a manuscript reviewer for leading publishers such as Nature, Wiley, and Elsevier.

Legacy and Future Contributions 🌟

Dr. Peng Shi’s work is paving the way for the next generation of therapeutic technologies and bioelectronic systems. By fostering interdisciplinary collaborations and mentoring emerging scholars, he is shaping the future of biomedical engineering. His patents and spin-offs ensure that his innovations continue to benefit society, bridging the divide between academia and industry.

Looking forward, Dr. Shi is poised to expand his influence through groundbreaking discoveries in synthetic biology, neuro-engineering, and artificial intelligence, driving advancements in healthcare and enhancing human well-being. His legacy will undoubtedly inspire future researchers and innovators, cementing his status as a transformative figure in biomedical engineering.

Notable Publication

Multifunctional Hydrogel Electronics for Closed-loop Antiepileptic Treatment

  • Authors   :Yuan WANG; Guangyu ZHU; Shu Chen; Chenjie Xu; Kai Xie; Jin Qu; Peng SHI; xingdao he
  • Journal    : Science Advances
  • Year         :2024

Few-shot meta-learning applied to whole brain activity maps improves systems neuropharmacology and drug discovery

      • Authors   : Xuan Luo; Yanyun Ding; Yi Cao; Zhen LIU; Wenchong Zhang; Shangzhi Zeng; Shuk Han Cheng; Honglin Li; Stephen J
      • Journal    : iScience
      • Year         :2024

Integrated Piezoelectric Vascular Graft for Continuous Real-Time Hemodynamics Monitoring

  • Authors   : Zhiqiang Ma; Weibin Jia; Jing ZHANG; xingdao he; Shiyuan Liu; Mohamed Elhousseini Hilal; Xiang ZHOU
  • Journal    : Functional Materials
  • Year         :2024

Nanopores-templated CNT/PDMS Microcolumn Substrate for the Fabrication of Wearable Triboelectric Nanogenerator Sensors to Monitor Human Pulse and Blood Pressure

  • Authors   :Tao Zhang; Chuanjie Yao; Xingyuan Xu; Zhibo Liu; Zhengjie Liu; Tiancheng Sun; Shuang Huang.
  • Journal     : Materials Technologies
  • Year         :2024                                                                                                                                                                                                                                                                                                                                                                                                          

Deciphering the Temporal–Spatial Interactive Heterogeneity of Long Non-Coding RNAs and RNA-Binding Proteins in Living Cells at Single-Cell Resolution

  • Authors   : Deyuan Yang; Cheng Li; Yutong Kong; Yian Pei; Bing Miao; Gaole Dai; Pi Ding; Peng Shi; Zixun
  • Journal     : American Chemical Society
  • Year         :2024